pharmacokinetic News
-
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that four abstracts highlighting LYR-210 results in chronic rhinosinusitis and the XTreo™ platform have been ...
-
Nanoparticulate Peptide Delivery Exclusively To The Brain Produces Tolerance Free Analgesia
There is pharmacological evidence of activity of MET enabled enkephalin in morphine-tolerant animals. We believe the preliminary data from these early animal studies of NES100 support our belief that Envelta™ may have comparable preclinical activity to morphine in all animal pain models tested without the drug seeking, respiratory depression, and tolerance associated with opioids. ...
-
Lipella Pharma Sees Positive Results for LP-10 Phase 2a Trial
Lipella Pharmaceuticals Inc. said it saw positive top-line results from its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis. The biotechnology company said its next step will be to communicate with the Food and Drug Administration on the study’s results and the pathway forward to seeking regulatory approval ...
-
Adiposs receives endorsement to proceed to Clinical Trials
We are thrilled to announce that following the scientific advice meeting with The Medicines and Healthcare products Regulatory Agency in the UK, Adiposs received endorsement for its flagship product, ImageBAT, to proceed to Clinical Trials. ImageBAT is the state-of-the-art imaging product that makes brown adipose tissue visible with a fast and pain-free CT scan. It enables early detection ...
By Adiposs
-
Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions
Alfa Chemistry serves as an emerging pharmaceutical research organization with a mission to revolutionize the field of preclinical drug research with its wide range of comprehensive services. With a commitment to quality and excellence, Alfa Chemistry offers pharmacological analysis, drug safety evaluation, pharmacokinetic analysis, and bioanalytical services to streamline the drug development ...
-
Showcase
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. Because of liver enzyme elevations ...
-
Creative Proteomics Pronalyse Anounces PEGylated Protein Identification Methods for Drug Discovery
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development service for over 10 years. With years of experience in offering professional and high-quality products for academic use and pharmaceutical industries, Creative Proteomics announces diversified PEGylated protein analysis technologies, which can solve important ...
-
Preclinical development of a novel radiopharmaceutical bioconjugate with the potential to cross the blood brain barrier
CIS Pharma and the University of Applied Sciences in Basel were granted a two-year research program by the Swiss Nanoscience Institute, SNI, to develop a nanobody-radionuclide conjugate, currently at preclinical stage. The bioconjugate is based on CIS Pharma’s polymer drug carrier technology and is developed to diagnose and treat B7H3-positive forms of cancer. The target plays a role in the ...
-
Ascelia Pharma’s Food Effect Study with Orviglance successfully completed
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the last patient visit has been completed in the study to evaluate the effect of food intake on the absorption of Orviglance (Mangoral). This Food Effect Study is part of the ongoing pivotal clinical program for Orviglance and will be included in the marketing authorization package to the health authorities including FDA and EMA. ...
-
Gesynta Pharma announces positive Phase I results with GS-248 for the treatment of microvascular disease - data to be presented at EULAR congress
Gesynta Pharma AB ("Gesynta") announces the completion and positive results of a first clinical study with GS-248. The purpose of the study was to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties of GS-248 after single and multiple ascending doses to healthy subjects. The results support the further clinical development of GS-248 in microvascular dysfunction and a ...
-
Araris Biotech AG to Present at 12th Annual World ADC London 2022
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Philipp Probst, Ph.D., Associate Director of ADC Research at Araris, will present data on the company’s linker technology at the 12th Annual World ADC London Conference. The poster presentation, titled, "Broadening the therapeutic index of antibody-drug conjugates ...
-
Dyve Biosciences to Highlight the Power and Potential ofTransdermal Drug Deliveryat PODD 2019
October 3,2019 –Thousand Oaks, California–Dyve Biosciences, a biotech drug delivery company developing breakthrough platform technology that broadly enables transdermal drug delivery, announcedtoday that its CEO,Ryan Beal,MD,will present at the Partnerships in Drug Deliveryconference (PODD), held October 7-8 in Boston. Beal co-invented Dyve’s novel transdermal delivery ...
-
Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF
Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has signed a clinical collaboration agreement with Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated ...
-
Creative Proteomics Pronalyse Releases Charge Heterogeneity Analysis Service for Protein Drug Discovery
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO with rich experience in providing drug development services for over 10 years. To assist customers in understanding the changes in protein charge heterogeneity throughout manufacturing and purification, Creative Proteomics Pronalyse offers antibody drug charge variant analysis services using isoelectric focusing or ion ...
-
Gesynta Pharma reports positive Phase I results with lead candidate GS-248 for microvascular disease at EULAR 2020
Gesynta Pharma AB ("Gesynta"), a clinical stage company developing novel anti-inflammatory agents, today announced that the results from the successfully completed First-in-Human clinical study with its lead candidate GS-248 for the treatment of microvascular disease have been presented at the EULAR 2020 E-Congress. Following these results, Gesynta now intends to commence a Phase II study in ...
-
Orion Biotechnology Successfully Completes Phase I Clinical Study of 0B-002H Topical Gel for HIV Prevention
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced successful completion of participant follow-up in their Phase 1 study of OB-002H which is an investigational candidate microbicide. The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic ...
-
Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 10:40am PT / 1:40pm ET. Please find additional details about the event ...
-
CD Formulation Releases Solubility Analysis to Assist Drug R&D Projects
Solubility measurement is a key element for a preliminary understanding of the pharmacodynamic properties of the drug. On August 30, 2021, CD Formulation, a leading CRO service provider in the industry, announces the release of drug solubility analysis, which is an indispensable step in drug development and formulation to ensure efficacy and quality of drugs. Drug substances have to be dissolved ...
-
CD Formulation Launches GalNAc Coupling Modification Services for the Development of Drug Delivery Systems
Over the past decade, the CD Formulation’s expert team has made tireless efforts in the research and development of drug delivery systems, trying to improve the pharmacokinetics and pharmacodynamics of drugs. In order to achieve the optimal therapeutic effect, the required dose must be delivered at the target site at the appropriate time and rate. “We have developed various drug ...
-
Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference on Wednesday, June 8, 2022, at 4:00pm ET. Please find additional ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you